David A. Siegel Kala Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.3 - $1.31 $7,080 - $30,916	-23,600 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.61 - $1.84 $732 - $2,208	-1,200 Reduced 4.84%	23,600 $33,000
Q4 2021 Feb 14, 2022	BUY	$1.16 - $2.74 $28,767 - $67,952	24,800 New	24,800 $30,000
Q2 2021 Aug 16, 2021	SELL	$5.06 - $8.15 $1.65 Million - $2.66 Million	-326,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.24 - $9.58 $429,936 - $660,062	-68,900 Reduced 17.41%	326,800 $2.2 Million
Q4 2020 Feb 16, 2021	BUY	$6.28 - $8.79 $2.24 Million - $3.14 Million	357,200 Added 927.79%	395,700 $2.68 Million
Q3 2020 Nov 16, 2020	SELL	$7.5 - $11.11 $345,000 - $511,060	-46,000 Reduced 54.44%	38,500 $289,000
Q2 2020 Aug 14, 2020	BUY	$8.33 - $13.79 $516,460 - $854,980	62,000 Added 275.56%	84,500 $888,000
Q1 2020 May 15, 2020	BUY	$3.83 - $8.79 $86,175 - $197,774	22,500 New	22,500 $198,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $9.81M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.